RxDoctor Payments DataLook up a doctor →

Susan Sipes

Interventional Pain Medicine · Greenwood, INNPI 1801335591

Payments from drug & device makers

$12,130in general payments, 2019–2025

Across 608 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • ANI Pharmaceuticals, Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Boston Scientific$1K
  • Vertos Medical, Inc.$559
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$12,118100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,130 in reported general payments places this provider in the 80th percentile of 68 interventional pain medicine providers in Indiana.

See all interventional pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$74,552
Medicare patients
154
Services billed
1,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CortrophinCorticotropin15$680,188
RelistorMethylnaltrexone Bromide13$30,455
QuliptaAtogepant24$25,560
UbrelvyUbrogepant18$23,778
BelbucaBuprenorphine Hcl28$19,359
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen726$18,434
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen684$16,536
Emgality PenGalcanezumab-Gnlm23$15,661
Xtampza ErOxycodone Myristate36$11,782
SavellaMilnacipran Hcl21$10,197
LinzessLinaclotide17$9,099
Gabapentin400$7,055
Pregabalin258$6,602
OxycontinOxycodone Hcl17$5,556
Oxycodone Hcl170$3,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Savella, Linzess$2,602$68,63480 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$1,022$31,14164 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,096$30,45513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 interventional pain medicine providers in Indiana.

Other interventional pain medicine in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →